novo nordisk weight loss drug

Hers, Hims and food and drug administration

Hims & Hers warns it may stop selling compounded weight-loss drugs

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.

CNBC on MSN · 5h

Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading.

FoodNavigator · 9h

A new generation of weight-loss drugs move beyond GLP-1

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are forcing the industry to think about nutrient-dense foods catering for those with smaller appetites.

Inc · 5d

These Drugs Could Offset the Side Effects of Weight Loss

Investopedia on MSN · 4h

Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins

Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales. The online healthcare provider’s fourth-quarter revenue nearly doubled year-over-year to $481.

FDA, Novo Nordisk and Wegovy and Ozempic

NBC New York · 3d

Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.

The Wall Street Journal on MSN · 3d

FDA Declares Shortage of Novo Nordisk’s Wegovy, Ozempic Over

The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and projected demand in the country, the Danish pharmaceutical company said.

WTXL ABC 27 · 2d

FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices

The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.

17h

Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk

Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...

Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

FiercePharma3d

Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

ABC News4d

Weight-loss drugs

Senators questioned Novo Nordisk CEO Lars Jørgensen on Tuesday at a hearing over the costs of Ozempic, Wegovy and similar weight loss drugs, which are cheaper in other countries. The CEO of ...

Weight-loss drugs are about to get a lot better

A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.

Are Weight Loss Injections Safe? What to Know Before Starting One

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Hers, Hims and food and drug administration

FDA, Novo Nordisk and Wegovy and Ozempic

Related topics